Navigation Links
Tennant tying forceps

ProductsTennant tying forceps
Company Katena Products, Inc.
Item Tennant tying forceps
Features 
Description Tennant stainless steel tying forceps is extra delicate, straight with smooth jaws, 6 mm long platform, round handle with guide pin. For 9-0 to 11-0 sutures.
Info Katena Products, Inc.
Customer Service: (800) 225-1195
Web site: http://www.katena.com/

Related medicine products :

1. Tennant straight tying forceps
2. Tennant angled tying forceps
3. Tennant curved tying forceps
4. Tennant Curved Tying Forceps
5. Tennant Straight Tying Forceps
6. McPherson tying forceps
7. Sinskey tying forceps
8. Anis tying forceps
9. Jaffe tying forceps
10. Maumenee tying forceps
11. Harms tying forceps
The best lens available for gonioscopy and laser trabeculoplasty. One 62 mirror. Tilted anterior surface corrects image and laser beam astigmatism. Unsurpassed resolution. Can be used on most patient
Mcintyre straight lachrymal cannula, closed end, two side ports at 0.3 mm, straight shaft.
Lachrymal cannula, straight.
The first easy-to use peroxide system offers proven efficacy that's pure and simple. The convenience of a multi-purpose cleaner/rinse in one bottle. Added power of peroxide in the other bottle.
Medicine Products:
(Date:12/3/2008)...e American College of Surgeons (ACS) today recogni...tee report on resident duty hours that was release...imizing Graduate Medical Trainee (Resident) Hours ... , ACS agrees with the IOM in its conclusion...ork week (averaged over four weeks) are not advisa...
(Date:12/3/2008)... -- Forest Laboratories, Inc. (NYSE: FRX ) today...ited mini-tender offer by TRC Capital Corporation ...pany. Forest Laboratories has received a copy of ...standing shares of the company,s common stock, whi...ing shares. The offer price of $20.35 per share r...
(Date:12/3/2008)...stCall/ -- MAP,Pharmaceuticals, Inc. (Nasdaq: M...icipate in a panel discussion titled "Adapting Spe...he 2008 RBC Capital Markets Healthcare Conference ... in New York City. , A live webcast of the ...,Relations section of MAP Pharmaceuticals, websit...
(Date:12/3/2008)...l-free recombinant albumin product manufactured by... serum in CHO cell culture. , ...Cellastim has proven to be a robust replacement fo...ve both the growth kinetics and productivity of CH...d media. , , ,Studies support InVitria,s claim tha...
Breaking Medicine News(10 mins):Health News:American College of Surgeons Comments on Institute of Medicine Report on Resident Duty Hours 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 3Health News:InVitria's Cellastim Delivers Superior Results in CHO Cell Culture 2
...ef new studies point in the direction that a dose ...breast cancer.// "High levels of daily stress are ...ncer". According to a study carried out at the Nat...h, Copenhagen. A group of over 6,500 women were fo...
...ng is responsible for checking the profits and saf...s sell to the NHS. They have to monitor that only ...ces should be reasonable. The Pharmaceutical Pric...y organization which monitors and legislates the a...
...tents, placement of stents that release the medica...e-narrowing nine months following angioplasty for ...ording to an article in the September 14 issue of ...nized the treatment of atherosclerotic coronary ar...
...ons have come up with a disaster-planning guide to...frequented by tropical storms, hurricanes, tidal w...n the world, people are vulnerable to some sort of...rthquake, flood, hurricane, or tornado. In additio...
Other Medicine News:Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Stents That Release Medication To Check Artery Narrowing 2Health News:Disaster Planning Guide From Harvard Health Publications 2
(Date:12/3/2008)...n, a contract development and,manufacturing organ...ined a,strategic financial partner to help it exp...d for Isogen,s services. , Isogen has previ... capital,investment and the opening of its first ...e previously unmet process, facility and capacity ...
(Date:12/3/2008)...stCall/ -- Bionovo, Inc.,(Nasdaq: BNVI ) today ...,manufacturing and control process descriptions (C... move forward with the development of Menerba,(fo... "We have concluded three CMC discussions wi...s recommendations for further development of Mener...
(Date:12/2/2008)... Researchers using functional,MRI (fMRI) have det...n,responsible for suppressing memory is dysfuncti...ychiatric disorders. Results of the study will be ...ological Society of North America,(RSNA). , ...ress-related disorders,traumatic memories are a ...
(Date:12/2/2008)...Call/ -- Biopure Corporation,(Nasdaq: BPUR ) an... Center,(NMRC) has submitted to the Food and Drug...ew drug (IND) application to conduct a clinical tr...R) [hemoglobin glutamer - 250 (bovine)],for the p...ts. The study is,entitled "Operation Restore Effe...
Breaking Medicine Technology:Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 2Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 4Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3BioReliance Corporation Launches iNet 28TM 29 for Online Results Tracking of Biological Safety Tests 641 1BioReliance Corporation Launches iNet 28TM 29 for Online Results Tracking of Biological Safety Tests 641 2ViPS Awarded Enterprise Systems Development 28ESD 29 Contract By CMS 636 1ViPS Awarded Enterprise Systems Development 28ESD 29 Contract By CMS 636 2ViPS Awarded Enterprise Systems Development 28ESD 29 Contract By CMS 636 3Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 1Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 2Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 3Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 4Wellcorps International Unveils New Nutritional Supplements 1444 1Wellcorps International Unveils New Nutritional Supplements 1444 2
...ernational Symposium,of Thrombosis and Haemostasis...Baxter,Healthcare Corporation today announced the ...of Data from ADVATE(R) Prospective Trials),study p...t,relationship between the duration of time spent ...nal unit per deciliter (1 IU/dL,one percent of no...
...-- Phase 3 results,from the RE-NOVATE(TM) trial de...ly, administered for an average of 33 days, was,no... average of 33,days, in preventing venous thromboe...hip replacement surgery. In this trial, the,rate o...ate was,similar to enoxaparin. The incidence of li...
Other Medicine Technology:Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 2Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 3Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 4Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 5Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 2Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 3Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 4Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 5